腹腔热灌注联合XELOX化疗方案治疗胃癌腹腔积液的效果  

Effect of Intraperitoneal Hyperthermic Perfusion Combined with XELOX Chemotherapy Regimen for the Treatment of Gastric Cancer Ascites

作　　者：张红巧[1] 刘鸥飞[1] 索丹风[1] 李玉 ZHANG Hongqiao;LIU Oufei;SUO Danfeng;LI Yu(Department of Oncology,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第五附属医院肿瘤内科,河南郑州450052

出　　处：《河南医学研究》2024年第15期2735-2738,共4页Henan Medical Research

摘　　要：目的观察腹腔热灌注重组人血管内皮抑制素注射液联合XELOX化疗方案(奥沙利铂+卡培他滨)治疗胃癌腹腔积液的临床效果。方法将2020年1月至2021年12月于医院接受XELOX化疗方案治疗的48例胃癌腹腔积液患者纳入对照组,将2022年1月至2022年12月接受腹腔热灌注重组人血管内皮抑制素注射液联合XELOX化疗方案治疗的48例胃癌腹腔积液患者纳入观察组。比较两组疗效、患者生命质量[采用卡氏功能状态量表(KPS)评估]。比较治疗前、治疗4个周期时患者免疫功能[T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))]。统计治疗期间不良反应发生情况。结果治疗4个周期时,观察组整体疗效优于对照组,治疗总有效率高于对照组(P<0.05)。治疗4个周期时,观察组生命质量改善率高于对照组(P<0.05)。治疗4个周期时,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前降低,但观察组各指标水平均高于对照组(P<0.05)。治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论在XELOX化疗方案基础上加用腹腔热灌注重组人血管内皮抑制素注射液治疗胃癌腹腔积液效果良好,可改善患者生命质量,减轻因化疗药物使用引起的免疫抑制,且不增加不良反应风险。Objective To observe the clinical efficacy of intraperitoneal hyperthermic perfusion of recombinant human endostatin injection(Endeavour)combined with XELOX chemotherapy regimen(oxaliplatin+capecitabine)in the treatment of gastric cancer ascites.Methods To include 48 patients with gastric cancer ascites who were treated with XELOX chemotherapy regimen in hospital from January 2020 to December 2021 in the control group,and 48 patients with gastric cancer ascites who were treated with intraperitoneal hyperthermic perfusion combined with XELOX chemotherapy regimen in hospitals from January 2022 to December 2022 were included in the observation group.The efficacy and quality of life of two groups of patients[evaluated using the Karnofsky performance scale(KPS)]were compared.The patient’s immune function[T lymphocyte subpopulations(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))]before treatment and during the four cycles of treatment were compared.The occurrence of adverse reaction during treatment were counted.Results After 4 cycles of treatment,the overall efficacy of the observation group was better than that of the control group,and the total effective rate of treatment was higher than that of the control group(P<0.05).After 4 treatment cycles,the improvement rate of quality of life in the observation group was higher than that in the control group(P<0.05).After 4 cycles of treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in both groups decreased compared to before treatment,but the levels of all indicators in the observation group were higher than those in the control group(P<0.05).During the treatment period,there was no statistical difference in the incidence of toxic side effects between the two groups(P>0.05).Conclusion On the basis of XELOX chemotherapy regimen,the addition of intraperitoneal hyperthermic perfusion with Endeavour for the treatment of gastric cancer ascites has a good therapeutic effect,which can improve the patient’s quality of life,reduce immune suppression caused by chemotherapy drug use,and d

关 键 词：胃癌 恶性腹腔积液 化疗 腹腔热灌注 重组人血管内皮抑制素 生命质量 

分 类 号：R735.2[医药卫生—肿瘤]